References
- 1. Kimura N, Yamamoto Y, Kameyama R, Hatakeyama T, Kawai N, Nishiyama Y. Diagnostic value of kinetic analysis using dynamic 18F-FDG-PET in patients with malignant primary brain tumor. Nucl Med Commun 2009; 30: 602-9.
- 2. Heald AE, Hoffman JM, Bartlett JA, Waskin HA. Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET). Int J STD AIDS 1996; 7: 337-46.
- 3. Pierce MA, Johnson MD, Maciunas RJ, Murray MJ, Allen GS, Harbison MA, et al. Evaluating contrast-enhancing brain lesions in patients with AIDS by using positron emission tomography. Ann Intern Med 1995; 123: 594-8.
- 4. Di Chiro G. Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol 1987; 22: 360-71.
- 5. Kuwabara Y, Ichiya Y, Otsuka M, Miyake Y, Gunasekera R, Hasuo K, et al. High [18F]FDG uptake in primary cerebral lymphoma: a PET study. J ComputAssist Tomogr 1988;12: 47-8.
- 6. Mohile NA, Deangelis LM, Abrey LE. The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro Oncol 2008; 10: 223-8.
- 7. Mohile NA, Deangelis LM, Abrey LE. Utility of brain FDG-PET in primary CNS lymphoma. Clin Adv Hematol Oncol 2008; 6: 818-20, 840.
- 8. Kawai N, Okubo S, Miyake K, Maeda Y, Yamamoto Y, Nishiyama Y, et al. Use of PET in the diagnosis of primary CNS lymphoma in patients with atypical MR findings. Ann Nucl Med 2010; 24: 335-43.
- 9. Palmedo H, Urbach H, Bender H, Schlegel U, Schmidt-Wolf IG, Matthies A, et al. FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up. Eur J NuclMed Mol Imaging 2006; 33: 164-8.
- 10. Rosenfeld SS, Hoffman JM, Coleman RE, Glantz MJ, Hanson MW, Schold SC. Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography. J Nucl Med 1992; 33: 532-6.
- 11. Karantanis D, O’Eill B P, Subramaniam RM, Witte RJ, Mullan BP, Nathan MA, et al. 18F-FDG PET/CT in primary central nervous system lymphoma in HIVnegative patients. Nucl Med Commun 2007; 28: 834-41.
- 12. Karantanis D, O’Neill BP, Subramaniam RM, Peller PJ, Witte RJ, Mullan BP, et al. Contribution of F-18 FDG PET-CT in the detection of systemic spread of primary central nervous system lymphoma. Clin Nucl Med 2007; 32: 271-4.
- 13. Nishiyama Y, Yamamoto Y, Monden T, Sasakawa Y, Kawai N, Satoh K, et al. Diagnostic value of kinetic analysis using dynamic FDG PET in immunocompetent patients with primary CNS lymphoma. Eur J Nucl Med Mol Imaging 2007; 34: 78-86.
- 14. Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005; 23: 5034-43.
- 15. Kiewe P, Fischer L, Martus P, Thiel E, Korfel A. Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis. Cancer 2008; 112: 1812-20.
- 16. Korfel A, Martus P, Nowrousian MR, Hossfeld DK, Kirchen H, Brucher J, et al. Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma. Br J Haematol 2005; 128: 177-83.